Enfortumab vedotin-ejfv (Padcev)
Reconstitution and dilutionFull monograph review pending
U.S. label preparation
Padcev · Reconstitution and dilution
- Preparation
- Add sterile water for injection to the vial: 2.3 mL for 20 mg or 3.3 mL for 30 mg. Both yield 10 mg/mL. Dilute to 0.3 to 4 mg/mL with 5% dextrose, 0.9% sodium chloride or lactated Ringer's.
- Administration and handling
- Gently invert the bag and infuse over 30 minutes. Follow hazardous drug precautions and monitor the IV site for extravasation.
Product and source details
SEAGEN INC. · BLA761137
Product NDC: 51144-020, 51144-030
SPL effective 2026-08-04 | SPL version 18. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.